Ceapro Inc V.CZO

The big one...

[prophetoffactz]

"Further, over the past quarter we remained very active with strategic corporate initiatives aimed towards achieving a stated objective related to uplisting Ceapro to an international stock exchange." news release

The company continues to be "very active" towards the objective of listing on NASDAQ.
Such an event could put a value on CZO's pipeline with the avenanthramide clinical trial about to dose its first patients, the 5X PGX scale-up expected to be completed by the end of the year and commissioned in Q1 2024, and with the comapny closing in on a clinical trial decision for the fibrosis product which Dr. Martin Kolb has said could profoundly change the landscape for fibrosis treatment if preclinical results are replicated. Reordering from CZO's major customer could also be near as CZO and Symrise also word towards the launch of dry powder formulations of avenanthramide and oat beta glucan which could expand the market. The Angiogenesis Foundation is also working towards completing its research on wound healing opening the door to a potential partnership deal. The avenanthramide malted techology is also advancing as CZO further has designed a an animal model protocol to test the immune stimulating properties of PGX-YBG vs. the competition. 

DO we take this to mean it's only a matter of time before Kenvue, CZO's major client, returns? 

• Developed powder formulation of high avenanthramides concentration for enriched skin formulations. Of note, Ceapro’s partner Symrise relaunched under a solid form an avenanthramide derivative product that they had marketed for almost two decades. While this relaunched analog is a byproduct from another oat-based extracted product not sold by Ceapro, it is produced in very small volumes and does not compete with Ceapro’s products nor with Symrise-Ceapro exclusive customers. However, the relaunch of this product by Symrise might be a proof of concept demonstrating an appetite from the cosmeceutical market to use powder formulations. Symrise and Ceapro are jointly assessing such potential opportunities.